05/23/23 8:04 AMNYSE : AORT, BAX Artivion Announces FDA PMA Approval of PerClot and Transfer of PMA to BaxterArtivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration granted premarket application approval of PERCLOT Absorbable Hemostatic System...RHEA-AIvery positive
05/04/23 4:05 PMNYSE : AORT earningsArtivion Reports First Quarter 2023 Financial ResultsAchieved revenue of $83.2 million in the first quarter of 2023 versus $77.2 million in the first quarter of 2022, an increase of 8% on a GAAP basis and an increase of 10% on a non-GAAP constant currency basis On-X revenues increased 23% on a GAAP basis and 24% on a non-GAAP constant currency basis in the first quarter of 2023 compared to the first quarter of 2022...RHEA-AIneutral
04/20/23 4:10 PMNYSE : AORT earningsArtivion Announces Release Date and Teleconference Call Details for First Quarter 2023 Financial ResultsArtivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2023 financial results will be released on Thursday, May 4, 2023 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer...RHEA-AIneutral
04/10/23 4:10 PMNYSE : AORT conferencesArtivion to Participate in the 22nd Annual Needham Virtual Healthcare ConferenceArtivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming 22 nd Annual Needham Virtual Healthcare Conference. A live webcast of the virtual fireside chat will be accessible through Artivion's website, www.artivion.com, on the Investors page.RHEA-AIneutral
03/06/23 4:10 PMNYSE : AORT conferencesArtivion to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceArtivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 33 rd Annual Healthcare Conference. A live webcast of the virtual fireside chat will be accessible through Artivion's website, www.artivion.com, on the Investors page.RHEA-AIneutral
02/16/23 4:05 PMNYSE : AORT earningsArtivion Reports Fourth Quarter and Full Year 2022 Financial ResultsArtivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, today announced its financial results for the fourth quarter and full year ended December 31, 2022. Asia Pacific and Latin American revenue grew 30% and 38%, respectively, on a constant currency basis compared to last year. During the fourth quarter, revenue growth was...RHEA-AIpositive
02/02/23 8:30 AMNYSE : AORT earningsArtivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2022 Financial ResultsArtivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2022 financial results will be released on Thursday, February 16, 2023 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a...RHEA-AIneutral
11/08/22 4:25 PMNYSE : AORT conferencesArtivion to Participate in Upcoming Investor ConferencesArtivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.Artivion's management team will present at the upcoming Stifel 2022RHEA-AIneutral
11/03/22 4:05 PMNYSE : AORT earningsArtivion Reports Third Quarter 2022 Financial ResultsThird Quarter and Recent Business Highlights:Achieved revenue of $76.8 million in the third quarter of 2022 versus $72.2 million in the third quarter of 2021, an increase of 6% on a GAAP basis and 11% on a non-GAAP constant currency basis On-X revenues increased 17% on a GAAP basis and 19% on aRHEA-AIpositive
10/20/22 8:25 AMNYSE : AORT earningsArtivion Announces Release Date and Teleconference Call Details for Third Quarter 2022 Financial ResultsArtivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2022 financial results will be released on Thursday, November 3, 2022 after the market closes. On that day, the CompanyRHEA-AIneutral